Loves makin money!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OXGN ASH play. December 7th presentation
http://investor.oxigene.com/releasedetail.cfm?ReleaseID=884074
/caerus/
Agreed. but as im sure you know these play can only run on market sentiment for so long until people realize its way overbought.. I understand these plays (aka trades)run on emotion, but there MAY actually be an INVESTMENT opportunity down here in POS penny stock world. I'll have to see next quarters results tho...
Thanks for the response!
/caerus/
If your INVESTING in a company wouldn't want to at least want to buy it around its intrinsic value (which we have no idea in this case)???
A company is a company regardless of what exchange it trades on a don't agree with your premise.
But thanks for the insight!
/caerus/
Doesn't any think this company is a bit over valued??
There were 4,117,470,000 shares outstanding as of the last 10Q.
That evaluates the company around $121,465,365 @ $.0295.
They made 1.3million last quarter, but that's without paying employees a salary and other expenses. Plus now theyre going to have actually spend money developing things like greenpay and other future systems.
If this company made $5million in earnings this year which is a fair expectation imo, the stock price is currently trading around 25-30 these expected earnings.. That sounds a bit to me
Someone help me out here with my evaluation because I don't understand why its valued over $121million right
http://www.otcmarkets.com/financialReportViewer?symbol=MYEC&id=121262
/caerus/
market should be quite volitile the next few weeks. a lot of money to be made day trading SPY options =)
/caerus/
whens the 10Q due out???
/caerus/
13:53 Sounds like not only have they identified a EU partner but they're gonna finish up the documentation very soon. looking forward to hearing about that!!
http://wsw.com/webcast/jmp21/NAVB/
/caerus/
Radioloyalty cracks top 1000 most used websites in Kazakhstan!!
/caerus/
you need to think of debt size & debt growth relative to GDP & GDP growth. I do not think the debt is as big a problem as many our thinkin... Japan owes over 200% of its GDP and its economy still operates better than most. Besides 75% of the debt is in house, which is still a HUGE problem but its not like we owe 16trillion to other nations like china and japan.
also I don't agree with :
"many who now do not have enough money for simple living expenses will be taxed out of any extra capital that they might have to purchase extra items after needs are met. This will have an almost immediate impact on the economy and the stock market"
they will not be taxed into despair... this is just silly that's not how the system has ever been or ever will be. the average consumer saving are at the highest on over a decade. They will not lose money
/caerus/
pardon me for jumping the gun =). I would like to hear your theory
/caerus/
artificially low? what shorts have covered??? I'm not convinced anymore that the shorts kept this artificially down at least not the past 2 months. The price was artificially kept high by the shorts before the PDUFA date if you ask me
/caerus/
I think we see a run into the shareholder meeting coming up in about 2 weeks. Anticipation of tilmanocept sales
/caerus/
More importantly closed above 50 dma!! MMs could let this run
/caerus/
But he is majority shareholder so he might be in charge of the decisions. Idk
/caerus/
http://streamtrackmedia.com/about-us/
Hill runs RL which is the subsidy
/caerus/
Combo of Aaron and James fault. CEO and IR
Hill runs RL
Bad marketing call. What a waste of shareholder money
/caerus/
Dude you need to relax. All you do is bash. It's only been 3 months since FDA approval. In the scale of the companies history that's nothing. If you can't realize that this is an investment in the NAVB pipeline then you need to move on and sell. Noone wants to hear you complain anymore
/caerus/
There are a few catalysts due out the next few months right? Something tells me sttk will be a 20 bagger by the end of the year
/caerus/
just the snippet about QS. There is no need for self promotion of QS in the ibox. its just embarrassing for everyone
This is what I want gone:
QualityStocks
3370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
Phone: (480) 374-1336
www.QualityStocks.net
Editor@QualityStocks.net
/caerus/
Thi page is meant to promote sttk not qualitystocks. Please remove promotion from quality stocks from ibox
Thanks
/caerus/
so why is the OWM and PPTV partnership so huge for STTK?? well here's one good reason
Radioloyalty's Regional Traffic Ranks
Country , Rank
Kazakhstan:3,747
United States: 8,149
Canada: 10,185
Philippines:10,754
Argentina: 14,607
Israel: 19,240
Poland:21,443
Romania: 22,508
Netherlands: 26,074
United Kingdom: 27,922
Australia: 41,477
India: 135,625
Germany:161,953
as you can see RL doesn't have much of a presence in the Asian markets. however this alliance will strengthen their presence and increase revenues!
Pptv.com’s Regional Traffic Ranks
Country , Rank
China: 192
Hong Kong: 421
South Korea: 515
Taiwan: 932
Japan: 2,977
United States: 13,542
/caerus/
Check out the newest station from One World Radio TV - K Pop!!!! you know what this means =)!!
https://www.facebook.com/RadioLoyalty?fref=ts
http://player.radioloyalty.com/station/9763.html
/caerus/
Radioloyalty broke top 5000 most viewed sites in kazakhstan! Didn't see that coming
/caerus/
Anyone know when the 10Q comes out?
/caerus/
Radioloyalty cracked top 10000 for Canada! Looking like profits for this quarter will be superb!
/caerus/
Can you please post a link?? Tia
/caerus/
I think people also forget that the share price was so high because the shorts ran the price up. They artificially inflated the pps. I am very bullish on this stock long term. But the stock needed and needs a cleanse. From the looks of volume NAVB is still not at a price were trade is mutually beneficial at least for buyers ( IMO of course). Take advantage of this consolidation and invest wisely. I know I am!
/caerus/
You hit the nail on the head. A huge chunk of the short position developed because of the delay to market. The delay turned this one into a race against the clock. Can navb bring its pipeline to market before they run out of money? Canl ymphoseek consolidate enough market share before the cash runs out? IMO it'll all come down to two things: there nav5001 study showing strong results and lymphoseek getting at least 15% market share of the lymphatic mapping market by years end. Who knows what will happen..
/caerus/
radio loyalty up 2500 Facebook followers since this time last month! 9133 people and counting!
/caerus/
i see this stock as a toss up. it all comes down to the revenue/operating cost. IMO we will see this stock tading sideways until next quartes earnings are reported. NAVB is a fantastic trading oppertunity IMO!
/caerus/
don't worry about the earnings. the cash is what's important. the major flaw with the biopharmaceutical business model is that it consumes an insane amount of money. ppl aren't sure if they'll be able to develop its pipeline and still have the cash to do it.
/caerus/
Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek(R)
- First new lymphatic mapping drug approved in more than 30 years -
DUBLIN, Ohio, May 01, 2013 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the U.S. launch of Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. Lymphoseek was approved by the U.S. Food and Drug Administration (FDA) in March 2013.
As part of Navidea's U.S. distribution partnership, Cardinal Health is responsible for the sale and distribution of Lymphoseek to health care professionals through its existing network of nuclear pharmacies. Navidea is working closely with the company in all commercial activities and medical education programs for Lymphoseek.
"Commercialization of Lymphoseek in the U.S. marks a pivotal milestone for Navidea, and we are pleased to deliver this innovative diagnostic imaging agent to patients with breast cancer and melanoma, as we help advance the field of precision diagnostics," said Dr. Mark Pykett, Navidea's President and CEO. "With Cardinal Health's extensive reach and pre-eminent radiopharmacy network, combined with our own medical education activities now underway to engage target physician groups, we expect to begin driving optimal adoption of Lymphoseek throughout the U.S."
"We are very enthusiastic about exclusively supplying Lymphoseek through our more than 140 U.S. nuclear pharmacies at a time when lymphatic mapping continues to grow in importance for the diagnostic evaluation of cancer patients," said Sandra Wisniewski, Vice President of Marketing and Business Development for Cardinal Health Nuclear Pharmacy Services. "Through our collaborative efforts with Navidea, we have completed a comprehensive range of training and education programs and have a full portfolio of commercial tools to support a successful Lymphoseek commercialization."
Lymphoseek has been priced at $300 per patient procedure. Navidea has been working to ensure fair and equitable reimbursement for lymphatic mapping procedures using Lymphoseek. In the case of Medicare, Navidea believes these procedures are currently reimbursable under established codes, and expects to apply for and receive a unique pass-through code for Lymphoseek within a few months. Navidea and Cardinal Health will provide information and support to providers and payers to ensure that they can secure formulary status and appropriate payment.
According to the American Cancer Society, approximately 232,000 new cases of breast cancer and 77,000 new cases of melanoma are expected to be diagnosed in the United States in 2013. One of the procedures used by physicians to help in the diagnostic evaluation of breast cancer and melanoma is lymphatic mapping. Lymphatic mapping is a widely used procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Navidea estimates that lymphatic mapping is utilized in approximately 70% of these patients each year in the United States.
Conference Call for Investors
Navidea Biopharmaceuticals will host a conference call for investors, today at 8:30 a.m. EDT to discuss the Lymphoseek launch. Conference call dial-in information is included below.
Conference Call Information
----------------------------------------------------------------------------------------------------
TO PARTICIPATE LIVE: TO LISTEN TO A REPLAY:
----------------------------------------------- -----------------------------------------------
Date: May 1, 2013 Available until: May 15, 2013
Time: 8:30 a.m. EDT Toll-free (U.S.) Dial in # : (877) 660-6853
International Dial in # : (201) 612-7415
Toll-free (U.S.) Dial in # : (877) 407-8031
International Dial in # : (201) 689-8031
Replay passcode: 268
Account #: 413373
Conference ID #:
----------------------------
About Lymphoseek(R)
Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. Lymphoseek was approved by the U.S. Food and Drug Administration in March, 2013 for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. The Company anticipates continuing development of Lymphoseek into other solid tumor areas that may include head and neck cancers, prostate cancer, thyroid cancer, lung/bronchus cancers, colorectal cancer and others.
Accurate diagnostic evaluation of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 232,000 new cases of breast cancer, 77,000 new cases of melanoma and 67,000 new cases of head and neck/oral cancer are expected to be diagnosed in the United States in 2013.
Indication and Important Safety Information About Lymphoseek Indication Lymphoseek (technetium Tc 99m tilmanocept) Injection is a lymphatic mapping agent indicated for use with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.
Important Safety Information In clinical trials with Lymphoseek, no serious hypersensitivity reactions were reported, however Lymphoseek may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).
Prior to the administration of Lymphoseek, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of Lymphoseek administration, and patients observed for signs or symptoms of hypersensitivity following injection.
The most common adverse reactions are injection site irritation and/or pain (<1%).
FULL LYMPHOSEEK PRESCRIBING INFORMATION CAN BE FOUND AT: WWW.LYMPHOSEEK.COM
About Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek(R), NAV4694, NAV5001 and RIGScanTM - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130501005185r1&sid=cmtx4&distro=nx
SOURCE: Navidea Biopharmaceuticals, Inc.
CONTACT:
Navidea Biopharmaceuticals Brent Larson, 614-822-2330 Sr. VP & CFO or Stern Investor Relations, Inc. Investor Relations Beth DelGiacco, 212-362-1200
Copyright Business Wire 2013
/caerus/
Short interest report due out tonight right? Looking forward to see what it entails..
/caerus/
bothers me as well
/caerus/
Excellent close!
/caerus/
24million+ shorting NAVB AO latest short interest report
http://www.nasdaq.com/symbol/navb/short-interest
/caerus/
there's a huge short position right now. Ppl are being cautious because no one wants to be a bag holder. Over the past few trading sessions I've noticed wholesale buyers stepping in. Imo We're gonna be in the range until they've accumulated enough of the short position to let this go. Trade smart
/caerus/
I'm thinkin there gonna be even uglier this time around traffic was pretty unimpressive. alsoI doubt they have super good cpm rates (based of traffic). I'm looking forward much more to 2nd quarter earnings I think that's when we take off. Will be buying over the next few months! GLTY
/caerus/